文献速递头颈与中枢神经肿瘤

EB病毒DNA筛选的III期鼻咽癌减量放疗:单臂2期试验

Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial.
PubMed 文献 · Eur J Cancer · 2023-09-09

这项单臂、单中心2期试验评估低危(EBV DNA<4000拷贝/ml)III期鼻咽癌诱导化疗后完全/部分缓解且EBV DNA不可测者接受60 Gy调强放疗是否非劣于标准剂量。215例完成两周期诱导化疗,116例(54.0%)接受60 Gy,99例(46.0%)接受70 Gy;中位随访43.9个月,全组2年无进展生存率为90.7%(95%CI 86.8%-94.6%),60 Gy组为94.8%(95%CI 90.7%-98.9%)。最常见晚期毒性为1-2级口干(发生率54.3%),未观察到3级及以上长期不良事件。

要点

  • 低危III期鼻咽癌诱导化疗后缓解且EBV DNA不可测者接受60 Gy放疗,2年PFS为94.8%(95%CI 90.7%-98.9%)。
  • 全组215例中位随访43.9个月,2年PFS为90.7%(95%CI 86.8%-94.6%)。
  • 最常见晚期毒性为1-2级口干,发生率54.3%,未观察到3级及以上长期不良事件。

核心结论

  • 减量放疗(60 Gy)在诱导化疗敏感的低危III期鼻咽癌患者中与良好生存结局相关,且治疗相关毒性有限。

研究设计与样本

  • 单臂、单中心、2期临床试验,在中国开展,注册号NCT03668730。
  • 入组低危(EBV DNA<4000拷贝/ml)III期鼻咽癌患者,接受两周期诱导化疗。
  • 诱导化疗后完全/部分缓解且EBV DNA不可测者接受60 Gy调强放疗同步三周期顺铂;主要终点为2年无进展生存率。

主要发现

  • 215例完成两周期诱导化疗,其中116例(54.0%)接受60 Gy放疗,99例(46.0%)接受70 Gy放疗。
  • 全组215例中位随访43.9个月(IQR 39.8-46.2),2年PFS为90.7%(95%CI 86.8%-94.6%)。
  • 60 Gy组中位随访43.9个月(IQR 40.2-46.2),2年PFS为94.8%(95%CI 90.7%-98.9%)。
  • 最常见晚期毒性为1-2级口干,发生率54.3%;未观察到3级及以上长期不良事件,多数生活质量条目、领域及症状评分在6个月时恢复至基线。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiotherapy-related toxicities of nasopharyngeal carcinoma (NPC) caused by a standard dose of 70 Gy remain a critical issue. Therefore, we assessed whether a radiotherapy dose of 60 Gy was non-inferior to the standard dose in patients with low-risk stage III NPC with a favourable response to induction chemotherapy (IC). PATIENTS AND METHODS: We did a single-arm, single-centre, phase II clinical trial in China. Patients with low-risk (Epstein-Barr virus [EBV] DNA level <4000 copies/ml) stage III NPC were treated with two cycles IC. Patients with complete/partial response and undetectable EBV DNA level were assigned 60 Gy intensity-modulated radiotherapy concurrently with three cycles of cisplatin. The primary end-point was 2-year progression-free survival (PFS). This trial is registered with ClinicalTrials.gov, number NCT03668730. RESULTS: One patient quit because of withdrawal of informed consent after IC. In total, 215 patients completed two cycles of IC, after which 116 (54.0%) and 99 (46.0%) patients were assigned 60 and 70 Gy radiotherapy, respectively. For 215 patients, the 2-year PFS was 90.7% (95% CI, 86.8%-94.6%) with a median follow-up of 43.9 months (interquartile range [IQR], 39.8-46.2). For patients treated with 60 Gy radiotherapy, the 2-year PFS rate was 94.8% (95%CI 90.7%-98.9%) with a median follow-up of 43.9 months (IQR 40.2-46.2). The most common late toxicity was grade 1-2 dry mouth (incidence rate: 54.3%). No grade 3+ long-term adverse event was observed, and most quality-of-life items, domains, and symptom scores returned to baseline by 6 months. CONCLUSION: Reduced-dose radiation (60 Gy) is associated with favourable survival outcomes and limited treatment-related toxicities in patients with low-risk stage III NPC sensitive to IC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Guo SS, Yang JH, Sun XS, et al. Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial. Eur J Cancer. 2023. PMID: 37801967. doi:10.1016/j.ejca.2023.113336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。